Literature DB >> 15281431

Th1 cytokine pattern (IL-12 and IL-18) in bronchoalveolar lavage fluid (BALF) before and after treatment with interferon gamma-1b (IFN-gamma-1b) or colchicine in patients with idiopathic pulmonary fibrosis (IPF/UIP).

Katerina M Antoniou1, Michael G Alexandrakis, Katerina Sfiridaki, Ioanna Tsiligianni, Kostas Perisinakis, Eleni G Tzortzaki, Nikolaos M Siafakas, Demosthenes E Bouros.   

Abstract

BACKGROUND AND AIM: Characterization of the biologic effects of Th1 cytokines will enhance the understanding of idiopathic pulmonary fibrosis (IPF) pathogenesis and treatment selection. Th1 response is characterized by increased expression of IFN-gamma, interleukin (IL)-12 and IL-18. The present study aims to evaluate the role of Th1 cytokines and their possible changes in the bronchoalveolar lavage fluid (BALF), before and after treatment with IFN-gamma-1b or colchicine. PATIENTS AND METHODS: We studied prospectively 10 patients (8 male, 2 female) of median age 67 yr with histologically confirmed IPF/UIP. Patients were randomly assigned to receive either IFN-gamma-1b 200 microg sc (5 patients) or colchicine 1 mg qd (5 patients) plus prednisone 10 mg qd. BALF IL-12 and IL-18 levels were measured before and after treatment.
RESULTS: BALF IL-12 levels before and after treatment did not differ significantly between the two treatment groups. However, BALF IL-18 levels were significantly decreased after treatment with IFN-gamma-1b (mean +/- SD, 58.4 +/- 15.6 pg/mL vs 42.8 +/- 4.90 pg/mL, p < 0.05). A significant difference was also found after treatment with colchicine (mean +/- SD, 66.8 +/- 36.9 pg/mL vs 42.6 +/- 1.08 pg/mL, p < 0.01). A significant correlation was found between IL-18 BALF levels and the BALF neutrophils (r = 0.75, p = 0.024).
CONCLUSION: Our data suggest the potential role of IL-18 as an inflammatory marker in the pathogenetic pathway of IPF such as its possible downregulation by IFN-gamma-1b treatment. Further studies are needed in a higher number of patients in order to define the precise role of both cytokines during the immunoregulatory response with IFN-gamma-1b.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15281431

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN: 1124-0490            Impact factor:   0.670


  7 in total

1.  Bronchiolitis Obliterans and Pulmonary Fibrosis after Sulfur Mustard Inhalation in Rats.

Authors:  Matthew D McGraw; Marilyn M Dysart; Tara B Hendry-Hofer; Paul R Houin; Jaqueline S Rioux; Rhonda B Garlick; Joan E Loader; Russell Smith; Danielle C Paradiso; Wesley W Holmes; Dana R Anderson; Carl W White; Livia A Veress
Journal:  Am J Respir Cell Mol Biol       Date:  2018-06       Impact factor: 6.914

2.  Effect of Qingfei Huaxian Decoction combined with prednisone acetate on serum inflammatory factors and pulmonary function of patients with idiopathic pulmonary fibrosis.

Authors:  Lei Zhou; Hui Tian; Qiong Wang; Wuzhong Xiong; Xiang Zhou; Jingjing Yan
Journal:  Am J Transl Res       Date:  2022-08-15       Impact factor: 3.940

Review 3.  Pulmonary fibrosis: pathogenesis, etiology and regulation.

Authors:  M S Wilson; T A Wynn
Journal:  Mucosal Immunol       Date:  2009-01-07       Impact factor: 7.313

Review 4.  Colchicine for prevention of cardiovascular events.

Authors:  Lars G Hemkens; Hannah Ewald; Viktoria L Gloy; Armon Arpagaus; Kelechi K Olu; Mark Nidorf; Dominik Glinz; Alain J Nordmann; Matthias Briel
Journal:  Cochrane Database Syst Rev       Date:  2016-01-27

Review 5.  New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis: a potential role for stem cells in the lung parenchyma and implications for therapy.

Authors:  Mehrnaz Gharaee-Kermani; Margaret R Gyetko; Biao Hu; Sem H Phan
Journal:  Pharm Res       Date:  2007-03-01       Impact factor: 4.580

Review 6.  Angiogenesis in interstitial lung diseases: a pathogenetic hallmark or a bystander?

Authors:  Argyris Tzouvelekis; Stavros Anevlavis; Demosthenes Bouros
Journal:  Respir Res       Date:  2006-05-25

7.  Association of FcγRIIa R131H polymorphism with idiopathic pulmonary fibrosis severity and progression.

Authors:  Stylianos Bournazos; Jacob Grinfeld; Karen M Alexander; John T Murchison; William A Wallace; Pauline McFarlane; Nikhil Hirani; A John Simpson; Ian Dransfield; Simon P Hart
Journal:  BMC Pulm Med       Date:  2010-10-07       Impact factor: 3.317

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.